BioStem Technologies, Inc. (BSEM)
4.15
-0.22
(-5.03%)
USD |
OTCM |
May 06, 16:00
BioStem Technologies Cash from Financing (Quarterly) : 0.00 for Dec. 31, 2025
Cash from Financing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Financing (Quarterly) Benchmarks
| Plus Therapeutics, Inc. | 2.803M |
| Iovance Biotherapeutics, Inc. | 56.17M |
| Protokinetix, Inc. | 0.01M |
| GB Sciences, Inc. | 0.125M |
| Travere Therapeutics, Inc. | 4.204M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 2.828M |
| Cash from Investing (Quarterly) | -0.4368M |
| Free Cash Flow | 6.589M |
| Free Cash Flow Per Share (Quarterly) | 0.1423 |
| Free Cash Flow to Equity (Quarterly) | 2.447M |
| Free Cash Flow to Firm (Quarterly) | 2.391M |
| Free Cash Flow Yield | 7.65% |